



## Oral Programme

Sunday 16 September 2018	
09:00-14:00	Editors Meeting
13:00-18:30	Registration   Room: Aula
15:00-16:00	<b>Opening plenary session</b>
Room	Patria
15:00-15:10	<b>Opening remarks</b> by Conference chair Gregory A. Poland, <i>Editor in Chief, Vaccine and Mayo Clinic, USA</i> Recognition of the Winner of the Schneerson-Robbins Prize Carol J. Baker, <i>University of Texas Health Science Center, USA</i>
15:10-16:00	Edward Jenner Prize with VACCINE prize <b>[Key.02] Current problems in vaccinology</b> Stanley A. Plotkin <sup>1,2</sup> , <sup>1</sup> University of Pennsylvania, USA, <sup>2</sup> Vaxconsult, USA
16:00-17:30	Drinks Reception and Poster Session I Room: Aula
Monday 17 September 2018	
08:30-10:30	<b>Plenary session 1: Challenges and Achievements in Disease Eradication</b> Session chair: Anthony Fooks, <i>Animal and Plant Health Agency, UK</i>
Room	Patria
08:30-09:10	<b>[Key.03] Current status of rabies and prospects for the reduction of human rabies cases by 2030</b> Anthony Fooks, <i>Animal &amp; Plant Health Agency, UK</i>
09:10-09:50	<b>[Key.04] Rinderpest eradication: Lessons learned</b> Peter Roeder, <i>Independent Consultant, UK</i>
09:50-10:30	<b>[Key.05] Disease eradication in human populations: challenges and opportunities</b> Martin Friede, <i>World Health Organization, Switzerland</i>
10:30-11:00	Refreshment break   Room: Aula
11:00-13:00	<b>Breakout session 1: Vaccine Safety Science</b> Session Chair: Steve Jacobson, <i>Kaiser Permanente Research, USA</i>
Room	Patria
11:00-11:45	<b>[Inv.01] Monitoring benefits and risks of vaccines in the EU: Overview of multinational initiatives</b> Miriam Sturkenboom, <i>Julius Global Health University Medical Center, The Netherlands</i>
11:00-11:30	<b>[Inv.02] Vaccines for older adults: The necessity for overcoming a flagging immune system</b> Martin Friede, <i>World Health Organization, Switzerland</i>
11:30-11:45	<b>[O2.1] Towards plant-derived therapeutic vaccine against chronic hepatitis B</b> T. Pniewski*, M. Pyrski, M. Czyż, <i>Institute of Plant Genetics Polish Academy of Sciences, Poland</i>
11:45-12:00	<b>[O1.1] Application of systems vaccinology for evaluating and screening new adjuvant candidates for safe and efficient influenza vaccines in the preclinical and lot release test</b> T.M. Mizukami*, E.S. Sasaki <sup>1</sup> , H.M. Momose <sup>1</sup> , Y.H. Hiradate <sup>1</sup> , K.F. Furuhashi <sup>1</sup> , H.A. Asanuma <sup>2</sup> , H.K. Kusunoki <sup>1</sup> , I.H. Hamaguchi <sup>1</sup> , <sup>1</sup> National Institute of Infectious Diseases, Japan, <sup>2</sup> Influenza Research Center, National Institute of Infectious Diseases, Japan
11:00-11:30	<b>[O2.2] Zoster-related hospitalizations in Vojvodina, Serbia in the pre-vaccine era</b> S. Medic* <sup>1,2</sup> , Z. Lozanov-Crvenkovic <sup>2</sup> , V. Petrovic <sup>1,2</sup> , K. Anastasopoulou <sup>3</sup> , <sup>1</sup> Institute of Public Health of Vojvodina, Serbia, <sup>2</sup> University of Novi Sad, Serbia, <sup>3</sup> University of Patras, Greece
12:00-12:15	<b>[O1.2] Post-licensing safety profile of the trivalent influenza vaccine manufactured by Instituto Butantan from 2013 to 2017</b> V.L. Gattás*, P.E. Braga, M.E. Koike, M.B.B. Lucchesi, R.O. Piorelli, V. Queiroz, M.M.M. de Oliverira, A.R. Precioso, <i>Instituto Butantan, Brazil</i>
11:00-11:30	<b>[O2.3] A novel antigen delivery system via Fcγ receptors induces robust immune responses</b> C.J. Chiang, C.Y. Chen, C.C. Wu, H.W. Chen*, <i>National Health Research Institutes, Taiwan</i>

12:15-12:30	<p><b>[O1.3] An approach to establish an in vitro assay system for the safety assessment of influenza vaccines and adjuvants in pre-clinical and lot-to-lot consistency tests</b> H. Momose*, E. Sasaki, Y. Hiradate, H. Kusunoki, T. Mizukami, I. Hamaguchi, <i>National Institute of Infectious Diseases, Japan</i></p>	<p><b>[O2.4] Relationships of varicella zoster virus (VZV)-specific cell-mediated immunity and persistence of VZV DNA in saliva and the development of postherpetic neuralgia in patients with herpes zoster</b> S.Y. Park*<sup>1</sup>, J.Y. Kim<sup>2</sup>, J. Kwon<sup>2</sup>, M-C. Kim<sup>2</sup>, Y.P. Chong<sup>2</sup>, S.O. Lee<sup>2</sup>, S-H. Choi<sup>2</sup>, J.H. Woo<sup>2</sup>, Y.S. Kim<sup>2</sup>, S-H. Kim<sup>2</sup>, <sup>1</sup><i>Dongguk University, Republic of Korea</i>, <sup>2</sup><i>University of Ulsan College of Medicine, Republic of Korea</i></p>
12:30-12:45	<p><b>[O1.4] Exploring the relationship between parents' distrust of vaccines and beliefs that their children were harmed by vaccination</b> T. Rozbroj*<sup>1</sup>, A. Lyons<sup>1</sup>, J. Lucke<sup>1,2</sup>, <sup>1</sup><i>La Trobe University, Australia</i>, <sup>2</sup><i>University of Queensland, Australia</i></p>	<p><b>[O2.5] Evaluation of different adjuvant formulations for development of an inactivated Yellow Fever vaccine candidate</b> A.C. Cajaraville*, M. Pierre, P.C. Neves, E. Caride, S.M. Barbosa, L. Gaspar, M.A. Medeiros, <i>Biomanguinhos, FIOCRUZ, Brazil</i></p>
12:45-13:00	<p><b>[O1.5] Childhood vaccine hesitancy among pregnant women in rural Malaysia: a qualitative study on socio-cultural and contextual factors</b> N.H. Mohd Hasni*<sup>1</sup>, I.F. Osman<sup>2</sup>, T. Techasrivichien<sup>1</sup>, P.M. Musumari<sup>1</sup>, P. Suguimoto<sup>1</sup>, M. Ono-Kihara<sup>1</sup>, H. Larson<sup>3</sup>, M. Kihara<sup>1</sup>, <sup>1</sup><i>Kyoto University, Japan</i>, <sup>2</sup><i>Ministry of Health, Malaysia</i>, <sup>3</sup><i>London School of Hygiene and Tropical Medicine, UK</i></p>	
13:00-14:30	Lunch   Room: Aula	
14:30-16:30	<p><b>Breakout session 3: Vaccine/Immune Response Durability</b> Session Chair: Danny Altmann, <i>Imperial College London, UK</i></p>	<p><b>Breakout session 4: Influenza</b> Session Chair: Kathy Neuzil, <i>University of Maryland, USA</i></p>
Room	Patria	Bartok
14:30-15:00	<p><b>[Inv.03] How aging and obesity may affect human vaccine responses</b> Bonnie Blomberg*, M. Romero, A. Diaz, D. Frasca, <i>University of Miami Miller School of Medicine, USA</i></p>	<p><b>[Inv.04] Innovation in real-time surveillance for influenza burden and vaccine effectiveness</b> Alicia M. Fry, <i>Center for Disease Control and Prevention, USA</i></p>
15:00-15:15	<p><b>[O3.1] The impact of sex and race on immune responses to viral vaccines</b> I. Ovsyannikova*, R. Kennedy, G. Poland, <i>Mayo Clinic, USA</i></p>	<p><b>[O4.1] Application of a panel of universal antibodies against all and subtype influenza viral neuraminidases to the analyses of influenza viruses and commercial vaccines</b> C. Gravel<sup>1</sup>, C. Li<sup>2</sup>, K. Xu<sup>2</sup>, T. Doyle<sup>1,4</sup>, A. Hashem<sup>1</sup>, B. Jaentscheke<sup>1</sup>, E. Brown<sup>4</sup>, G. Van Domselaar<sup>3</sup>, J. Wang<sup>2</sup>, X. Li*<sup>1,4</sup>, <sup>1</sup><i>Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFD, Health Canada; WHO Collaboration Centre for Biologicals Standardization and Evaluation, Canada</i>, <sup>2</sup><i>National Institute for Food and Drug Control; WHO Collaboration Centre for Biologicals Standardization and Evaluation, China</i>, <sup>3</sup><i>National Microbiology Laboratory, Public Health Agency of Canada, Canada</i>, <sup>4</sup><i>University of Ottawa, Canada</i></p>
15:15-15:30	<p><b>[O3.2] Immunogenicity and memory B cell response post-booster and at 18 months of age following alternative pneumococcal vaccination strategies in Vietnam</b> P.V. Licciardi*<sup>1,2</sup>, T. Phan<sup>3</sup>, Z.Q. Toh<sup>1</sup>, <sup>1</sup><i>Murdoch Children's Research Institute, Australia</i>, <sup>2</sup><i>University of Melbourne, Australia</i>, <sup>3</sup><i>Pasteur Institute, Viet Nam</i>, <sup>4</sup><i>London School of Hygiene and Tropical Medicine, UK</i>, <sup>5</sup><i>Menzies School of Health Research, Australia</i></p>	<p><b>[O4.2] Global pandemic influenza vaccine preparedness: Progress under the global action plan for influenza vaccines and next steps</b> S. Goldin, C. Chadwick, C. Nannei*, <i>World Health Organization, Switzerland</i></p>
15:30-15:45	<p><b>[O3.3] DosR proteins Rv2627 and Rv2628 of Mycobacterium tuberculosis induce IFN-γ and down regulate T regulatory cells in TB infected individuals and their healthy contacts</b></p>	<p><b>[O4.3] The immunogenicity of live attenuated influenza vaccine in Gambian children: insights into reduced efficacy and effectiveness against pandemic H1N1</b></p>

	M. Sharma*, S. Sharma, <i>Miranda House, India</i>	B. Lindsey* <sup>1,2</sup> , Y.J. Jagne <sup>2</sup> , E.P. Armitage <sup>2</sup> , N.I. Mohammed <sup>2</sup> , S. Drammeh <sup>2</sup> , E. Senghore <sup>2</sup> , K. Hoschler <sup>3</sup> , T. Dong <sup>4</sup> , B. Kampmann <sup>1,2</sup> , T.I. de Silva <sup>1,2</sup> , <sup>1</sup> <i>Imperial College London, UK</i> , <sup>2</sup> <i>Medical Research Unit The Gambia at LSHTM, Gambia</i> , <sup>3</sup> <i>Public Health England, UK</i> , <sup>4</sup> <i>University of Oxford, UK</i>
15:45-16:00	<b>[O3.4] Efficacy of an adenoviral vector vaccine against Lassa fever</b> E.J. Mateer*, J. Maruyama, J.T. Manning, C. Huang, S. Paessler, <i>University of Texas Medical Branch, USA</i>	<b>[O4.4] Vaccinating guinea pigs with adjuvanted recombinant neuraminidase prevents influenza B virus transmission</b> M. McMahon* <sup>1</sup> , E. Kirkpatrick <sup>1</sup> , D. Stadlbauer <sup>1,2</sup> , N.M. Bouvier <sup>1</sup> , F. Krammer <sup>1</sup> , <sup>1</sup> <i>Icahn School of Medicine at Mount Sinai, USA</i> , <sup>2</sup> <i>University of Natural Resources and Life Sciences, Austria</i>
16:00-16:15	<b>[O3.5] Role of Type 3 Secretion System (T3SS) proteins in the induction of short- and long-term immune responses in humans vaccinated with live whole-cell vaccine</b> V.A. Feodorova* <sup>1,2</sup> , A.M. Lyapina <sup>1</sup> , M.A. Khizhnyakova <sup>1</sup> , S.S. Zaitsev <sup>1</sup> , L.V. Sayapina <sup>3</sup> , M.V. Telepnev <sup>4</sup> , O.V. Ulianova <sup>1</sup> , E.P. Lyapina <sup>5</sup> , S.S. Ulyanov <sup>6</sup> , V.L. Motin <sup>4</sup> , <sup>1</sup> <i>Federal Research Center for Virology and Microbiology, Russia</i> , <sup>2</sup> <i>Saratov State Agrarian University, Russia</i> , <sup>3</sup> <i>Scientific Center on Expertise of Medical Application Products, Russia</i> , <sup>4</sup> <i>University of Texas Medical Branch, USA</i> , <sup>5</sup> <i>Saratov State Medical University, Russia</i> , <sup>6</sup> <i>Saratov State National Research University, Russia</i>	<b>[O4.5] A new, whole virion, aluminum adjuvanted, reduced dose seasonal influenza vaccine is safe and immunogenic in children and adolescents</b> Z. Vajo*, L. Kalabay, P. Vajo, G. Balaton, P. Torzsa, <i>Semmelweis University, Hungary</i>
16:15-16:30	<b>[O3.6] Mucosal inflammatory cytokine/chemokine responses to different modalities of candidate HIV vaccines in Mauritian cynomolgus macaques</b> N. Toledo <sup>1</sup> , H. Li <sup>1</sup> , R. Omange <sup>1</sup> , T. Gomez <sup>3</sup> , J. Crecente-Campo <sup>3</sup> , D. Schalk <sup>2</sup> , E. Rakas <sup>2</sup> , N. Schultz-Darken <sup>2</sup> , M. Alonso <sup>3</sup> , M. Luo* <sup>1,5</sup> , <sup>1</sup> <i>University of Manitoba, Canada</i> , <sup>2</sup> <i>Wisconsin National Primate Research Center, USA</i> , <sup>3</sup> <i>University of Santiago de Compostela, Spain</i> , <sup>4</sup> <i>National Microbiology Laboratory, Public Health Agency of Canada, Canada</i> , <sup>5</sup> <i>Harvard Medical School, USA</i> , <sup>6</sup> <i>University of Nebraska-Lincoln, USA</i>	<b>[O4.6] Profiling the effect of obesity on the influenza vaccine-induced Ab repertoire using antigen microarrays</b> M. Abd Alhadi* <sup>1,2</sup> , T. Hertz <sup>1,2</sup> , L. Fridman <sup>1,2</sup> , E. Karlsson <sup>4</sup> , M. Beck <sup>5</sup> , <sup>1</sup> <i>Ben Gurion University, Israel</i> , <sup>2</sup> <i>National Institute of biotechnology, Israel</i> , <sup>3</sup> <i>Fred Hutchinson Cancer Research Center, USA</i> , <sup>4</sup> <i>Virology Institut Pasteur du Cambodge, Cambodia</i> , <sup>5</sup> <i>University of North Carolina, USA</i>
16:30-17:00	Refreshment break   <i>Room: Aula</i>	
17:00-18:00	<b>Breakout session 5: The role of the private sector in vaccines and public health: Challenges and opportunities</b> Session Chair: Bruce Lee, <i>Johns Hopkins University, USA</i>	
Room	<i>Patria</i>	
	Panel discussion- Panelists: <b>Stanley Plotkin</b> , <i>VaxConsult, USA</i> <b>Seb Taylor</b> , <i>Royal College of Paediatrics and Child Health, UK</i> <b>Valerie Oriol Mathieu</b> , <i>Janssen Infectious Diseases and Vaccines, The Netherlands</i>	
18:00-19:30	Drinks Reception and Poster Session 2	
Room	<i>Aula</i>	
<b>Tuesday 18 September 2018</b>		
08:30-10:30	<b>Plenary session 2: Overcoming vaccine hesitancy</b> Session Chair: Steve Jacobson, <i>Kaiser Permanente Research, USA</i>	
Room	<i>Patria</i>	
08:30-09:10	<b>[Key.06] Understanding and addressing vaccine hesitancy</b> Daniel Salmon, <i>John Hopkins University, USA</i>	
09:10-09:50	<b>[Key.07] Effective interventions to improve vaccine-related attitudes and increase vaccine acceptance</b> Matthew F. Daley* <sup>1</sup> , J.M. Glanz <sup>1</sup> , <sup>1</sup> <i>University of Colorado School of Medicine, USA</i> , <sup>2</sup> <i>Colorado School of Public Health, USA</i>	
09:50-10:30	<b>[Key.08] New approaches to measuring barriers to immunisation, developing evidenced-based interventions and evaluation of vaccine policy in Australia</b> Margie Danchin, <i>Murdoch Children's Research Institute, Australia</i>	
10:30-11:00	Refreshment break   <i>Room: Aula</i>	

<b>11:00-12:30</b>	<b>Breakout session 6: New vaccine adjuvants and delivery systems</b> Session Chair: Ken Ishii, <i>National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan</i>	<b>Breakout session 7: Zoonosis and veterinary vaccines</b> Session Chair: Sylvia van den Hurk, <i>University of Saskatchewan, College of Medicine - VIDO-Intervac, Saskatoon, Canada</i>
<i>Room</i>	<i>Patria</i>	<i>Bartok</i>
<b>11:00-11:30</b>	<b>[Inv.05] The nasal immune system for the vaccine development</b> Hiroshi Kiyono <sup>1,2</sup> , <sup>1</sup> <i>University of California, USA</i> , <sup>2</sup> <i>The University of Tokyo, Japan</i>	<b>[Inv.06] Food and water safety: Vaccines for zoonotic diseases</b> Andrew Potter, <i>VIDO-InterVac, Canada</i>
<b>11:30-11:45</b>	<b>[O6.1] Mode-of-Action (MOA) of a particulate adjuvant</b> M.S.J. Lee <sup>1</sup> , K.J. Ishii <sup>1,2</sup> , C. Coban <sup>*1</sup> , <sup>1</sup> <i>Osaka University, Japan</i> , <sup>2</sup> <i>NIBIOHN, Japan</i>	<b>[O7.1] Four-segmented Rift Valley fever virus is safe and protective in pregnant ewes</b> P.J. Wichgers Schreur <sup>1,3</sup> , J. Oymans <sup>1,2</sup> , J. Kant <sup>1</sup> , S. van de Water <sup>1</sup> , J. Kortekaas <sup>*1,3</sup> , <sup>1</sup> <i>Wageningen Bioveterinary Research, The Netherlands</i> , <sup>2</sup> <i>Wageningen University and Research, The Netherlands</i> , <sup>3</sup> <i>BunyaVax, The Netherlands</i>
<b>11:45-12:00</b>	<b>[O6.2] Comparison of PLGA nanocarriers for initiating immunogenicity</b> K. Kaneko <sup>*1</sup> , E. Miyaji <sup>2</sup> , V. Goncalves <sup>2</sup> , D. Ferreira <sup>3</sup> , C. Solorzano-Gonzalez <sup>3</sup> , R. MacLoughlin <sup>4</sup> , D. Sexton <sup>1</sup> , I. Saleem <sup>1</sup> , <sup>1</sup> <i>Liverpool John Moores University, UK</i> , <sup>2</sup> <i>Butantan Institute, Brazil</i> , <sup>3</sup> <i>Liverpool School of Tropical Medicine, UK</i> , <sup>4</sup> <i>Aerogen Limited, Ireland</i>	<b>[O7.2] Development of a dual-target rabies/yellow fever vaccine candidate</b> L. Sanchez-Felipe <sup>*1</sup> , N. Mishra <sup>1</sup> , S. Sharma <sup>1</sup> , S. Terryn <sup>2</sup> , A.C. Banyard <sup>3</sup> , A.R. Fooks <sup>3</sup> , S. Van Gucht <sup>2</sup> , J. Neyts <sup>1</sup> , K. Dallmeier <sup>1</sup> , <sup>1</sup> <i>KU Leuven, Belgium</i> , <sup>2</sup> <i>Sciensano, Belgium</i> , <sup>3</sup> <i>Animal and Plant Health Agency (APHA), UK</i>
<b>12:00-12:15</b>	<b>[O6.3] Non-human papillomaviruses for gene delivery in vitro and in vivo</b> L.B. Bayer <sup>1</sup> , J.G. Gümpel <sup>1</sup> , G.H. Hause <sup>2</sup> , M.M. Müller <sup>3</sup> , T.G. Grunwald <sup>*1</sup> , <sup>1</sup> <i>Fraunhofer Institute for Cell Therapy and Immunology, Germany</i> , <sup>2</sup> <i>Biozentrum, Martin-Luther-University, Germany</i> , <sup>3</sup> <i>German Cancer Research Center, Germany</i>	<b>[O7.3] Mucosal immunization with hcp of type VI secretion system confers strong host immunity and efficiently reduce cecal colonization of Campylobacter jejuni in chickens</b> A. Singh <sup>*</sup> , K. Nisaa, A.I. Mallick, <i>Indian Institute of Science Education and Research, India</i>
<b>12:15-12:30</b>		<b>[O7.4] Structure-based MEFA (multiepitope fusion antigens) technology assists two multivalent antigens for immunogenicity against fifteen heterogeneous enterotoxigenic Escherichia coli (ETEC) adhesins (CFA/I, CS1-CS7, CS12, CS14, CS17, CS19, CS21, EtpA, EaeH)</b> Q.D. Duan <sup>1</sup> , N. Xiao <sup>1</sup> , H. Seo <sup>1</sup> , J. Huang <sup>1</sup> , D.A. Sack <sup>2</sup> , W. Zhang <sup>*1</sup> , <sup>1</sup> <i>Kansas State University, USA</i> , <sup>2</sup> <i>Johns Hopkins University, USA</i>
<b>12:30-13:30</b>	Meet the Editors speed review roundtable	
<b>12:30-13:30</b>	Lunch   <i>Room: Aula</i>	
<b>13:30-14:30</b>	<b>Author/Reviewer Workshop</b> Vaccine Journal and Gregory A. Poland, <i>Editor in Chief, Vaccine and Mayo Clinic, USA</i>	
<i>Room</i>	<i>Bartok</i>	
<b>14:30-16:30</b>	<b>Breakout session 8: Vaccines against mosquito and tick-borne diseases</b> Session Chair: Jose de la Fuente, <i>SaBio. Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM-JCCM), Spain and Oklahoma State University, USA</i>	<b>Breakout session 9: Herpes vaccines</b> Session Chair: Stanley Plotkin, <i>Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University, USA</i>
<i>Room</i>	<i>Patria</i>	<i>Bartok</i>
<b>14:30-15:00</b>	<b>[Inv.07] Taking advantage of the vector-host-pathogen arms race for development of vaccines against tick infestations and pathogen infection</b> Jose de la Fuente <sup>1</sup> , <sup>1</sup> <i>SaBio. Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM-JCCM), Spain</i> , <sup>2</sup> <i>Oklahoma State University, USA</i>	<b>[Inv.08] Vaccination against the human Cytomegalovirus</b> Stanley A. Plotkin <sup>1,2</sup> , <sup>1</sup> <i>University of Pennsylvania, USA</i> , <sup>2</sup> <i>Vaxconsult, USA</i>

15:00-15:15	<b>[O8.1] Selective restriction of Zika virus replication in the male reproductive organs using microRNA targeting approach reveals multiple routes for virus dissemination in the epididymis but not in the testis</b> K.A. Tsetsarkin*, G. Liu, H. Kenney, O. Maximova, N. Teterina, M. Bloom, J.M. Grabowski, L. Mlera, B. Nagata, I. Moore, <i>National Institute of Allergy and Infectious Diseases, USA</i>	15:00-15:30 <b>[Inv.09] Recombinant glycoprotein E adjuvanted herpes zoster vaccine</b> Myron J. Levin, <i>University of Colorado School of Medicine, USA</i>
15:15-15:30	<b>[O8.2] Use of a chimeric Japanese encephalitis vaccine as a potent alternative for yellow fever vaccination</b> N. Mishra* <sup>1</sup> , M.A. Schmid <sup>1</sup> , R. Boudewijns <sup>1</sup> , R.E. Marques <sup>1,2</sup> , J. Neyts <sup>1</sup> , K. Dallmeier <sup>1</sup> , <sup>1</sup> <i>University of Leuven, Belgium</i> , <sup>2</sup> <i>Centro Nacional de Pesquisa em Energia e Materiais Campinas, Brazil</i>	
15:30-15:45	<b>[O8.3] Development of novel, safe and efficacious single-dose vaccines; Zika, Ebola and Lassa fever as examples</b> F. Guirakhoo, <i>GeoVax, USA</i>	15:30-16:00 <b>[O9.1] Vaccines against Sudan ebolavirus and Marburg virus to meet emergency medical countermeasure needs</b> D. Wolfe*, E. Espeland, A. Zarrabian, <i>Biomedical Advanced Research and Development Authority, USA</i>
15:45-16:00	<b>[O8.4] A decavalent protein-based vaccine protects cattle against successive <i>R. microplus</i> infestations</b> A. Fisch*, L.G.N. de Almeida, M. Oliveira, I.P. Daher, I.K.F.M. Santos, B.R. Ferreira, <i>University of Sao Paulo, Brazil</i>	
16:00-16:15	<b>[O8.5] New strategies for the delivery of PLLAV-YF17D, a thermostable yellow fever vaccine launched from a plasmid</b> S. Sharma*, M.A. Schmid, N. Mishra, J. Neyts, K. Dallmeier, <i>KU Leuven – University of Leuven, Belgium</i>	<b>[O9.2] Laboratory surveillance of invasive <i>Haemophilus influenzae</i> disease and characterization of emergence of serotype a strains</b> R.S.W. Tsang*, M. Shuel, W. Hoang, <i>National Microbiology Laboratory, Canada</i>
16:15-16:30	<b>[O8.6] Characterisation and post-exit modification of cell-derived lipid nanovesicles for vaccine development</b> S. Heider <sup>1</sup> , M. Zaruba <sup>1</sup> , J.A. Dangerfield <sup>2</sup> , E. Reimhult <sup>3</sup> , C. Metzner* <sup>1</sup> , <sup>1</sup> <i>University of Veterinary Medicine, Austria</i> , <sup>2</sup> <i>Anovasia Pte. Ltd., Singapore</i> , <sup>3</sup> <i>University of Natural Resources and Life Sciences, Austria</i>	<b>[O9.3] Mucosal delivery of inactivated polio vaccine</b> H. Kraan*, P.C. Soema, G. Kersten, <i>Intravacc, The Netherlands</i>
16:30-17:00	Refreshment break   <i>Room: Aula</i>	
17:00-18:00	<b>Breakout session 10: Roundtable - Typhoid conjugate vaccine</b> Session Chair: Kathy Neuzil, <i>University of Maryland, USA</i>	
<i>Room</i>	<i>Patria</i>	
17:00-17:30	<b>[Inv.10] Time for Typhoid</b> Andrew Pollard, <i>University of Oxford, UK</i>	
17:30-18:00	<b>Roundtable</b>	
19:00-22:00	Conference Dinner (ticketed)	
<b>Wednesday 19 September 2018</b>		
08:30-10:30	<b>Plenary session 3: Delivering vaccines – why is it difficult and what are the solutions?</b> Session Chair: Gregory A. Poland, <i>Editor in Chief, Vaccine and Mayo Clinic, USA</i>	
<i>Room</i>	<i>Patria</i>	
08:30-09:10	<b>[Key.09] Injecting a dose of reality: A 12 step program to improving vaccine delivery in adults</b> Gregory A. Poland, <i>Vaccine and Mayo Clinic, USA</i>	
09:10-09:50	<b>[Key.10] Preventing disease through demand for vaccination: vaccines alone are not enough</b> Daniel Salmon, <i>John Hopkins University, USA</i>	
09:50-10:30	<b>[Key.11] A hemagglutinin stalk-based universal influenza virus vaccine</b> Florian Krammer, <i>Icahn School of Medicine at Mount Sinai, USA</i>	
10:30-11:00	Refreshment break   <i>Room: Aula</i>	
11:00-12:45	<b>Breakout session 11: Vaccine ‘Pot Pourri’ session</b> Session Chair: Florian Krammer, <i>Icahn School of Medicine at Mount Sinai, USA</i>	
<i>Room</i>	<i>Patria</i>	

11:00-11:15	<p><b>[O11.1] Low energy electron irradiation efficiently inactivates pathogens while preserving antigenic structures in protective formulation - a promising novel method for the generation of vaccines</b>  J. Fertey<sup>1</sup>, L.J. Bayer<sup>1</sup>, J. Schönfelder<sup>2</sup>, J. Portillo<sup>2</sup>, F-H. Rögner<sup>2</sup>, S. Bailer<sup>3</sup>, K. Kemter<sup>4</sup>, S. Hauck<sup>4</sup>, J. Altrichter<sup>4</sup>, T. Grunwald*<sup>1</sup>, S. Ulbert<sup>1</sup>, <sup>1</sup>Fraunhofer-Institute for Cell Therapy and Immunology, Germany, <sup>2</sup>Fraunhofer-Institute for Organic Electronics, Electron Beam and Plasma Technology, Germany, <sup>3</sup>Fraunhofer Institute for Interfacial Engineering and Biotechnology, Germany, <sup>4</sup>Leukocare AG, Germany</p>
11:15-11:30	<p><b>[O11.2] Nucleoside-modified mRNA vaccines induce potent T follicular helper cell and protective neutralizing antibody responses</b>  N. Pardi*<sup>1</sup>, M. Hogan<sup>1</sup>, A. Myles<sup>1</sup>, M. Naradikian<sup>1</sup>, K. Parkhouse<sup>1</sup>, D. Cain<sup>2</sup>, C. LaBranche<sup>3</sup>, D. Montefiori<sup>3</sup>, L. Sutherland<sup>2</sup>, F. Krammer<sup>5</sup>, <sup>1</sup>University of Pennsylvania, USA, <sup>2</sup>Duke Human Vaccine Institute, USA, <sup>3</sup>Duke University Medical Center, USA, <sup>4</sup>University of Washington, USA, <sup>5</sup>Icahn School of Medicine at Mount Sinai, USA</p>
11:30-11:45	<p><b>[O11.3] Modified dendrimer-RNA nanoparticles as a rapid, synthetic, broadly-applicable vaccine platform</b>  J. Chahal*<sup>1</sup>, O. Khan<sup>1</sup>, C. Cooper<sup>2</sup>, J. McPartlan<sup>1</sup>, S. Bavari<sup>2</sup>, H. Ploegh<sup>3</sup>, <sup>1</sup>Tiba Biotech, USA, <sup>2</sup>United States Army Medical Research Institute of Infectious Diseases, USA, <sup>3</sup>Boston Children's Hospital, USA</p>
11:45-12:00	<p><b>[O11.4] RNActive<sup>®</sup> - An mRNA-based vaccine technology for next generation prophylactic vaccines</b>  S. Rauch*, J. Lutz, S. Lazarro, E. Jasny, K. Schmidt, B. Petsch, CureVac AG, Germany</p>
12:00-12:15	<p><b>[O11.5] A chimeric yellow fever-Zika vaccine virus fully protects against lethal zika and yellow fever virus diseases in stringent murine challenge models</b>  D. Kum*, R. Boudewijns, J. Ma, N. Mishra, J. Neyts, K. Dallmeier, KU Leuven, Belgium</p>
12:15-12:30	<p><b>[O11.6] An mRNA vaccine overcomes maternal antibody inhibition of immune responses to influenza vaccines</b>  E. Willis*, N. Pardi, K. Parkhouse, D. Weissman, S. Hensley, University of Pennsylvania, USA</p>
12:30-12:45	<p><b>[O11.7] Novel correlates of protection against influenza A(H1N1)pdm virus infection</b>  R. Nachbagauer*<sup>1</sup>, S. Ng<sup>2</sup>, A. Balmaseda<sup>3,4</sup>, D. Stadlbauer<sup>1</sup>, S. Ojeda<sup>5</sup>, M. Patel<sup>2</sup>, A. Rajabhathor<sup>1</sup>, R. Lopez<sup>3,4</sup>, A.F. Guglia<sup>1</sup>, N. Sanchez<sup>4</sup>, <sup>1</sup>Icahn School of Medicine at Mount Sinai, USA, <sup>2</sup>University of Michigan, USA, <sup>3</sup>Ministry of Health, Nicaragua, <sup>4</sup>Sustainable Sciences Institute, Nicaragua</p>
12:45-13:15	<p><b>Closing Session and poster prize</b>  Boxed lunch available</p>
Room	Patria
14:00-17:00	Social Networking afternoon at own cost – please refer to the website for details of local tour providers